Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$189.6MCash on Hand
CF+ Cash Runway
Follow PHAR by emailGet an email when PHAR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PHAR, unsubscribe in one click. Privacy
💊 Upcoming FDA Decisions
PDUFA Date
Drug
Indication
Type
PoA
2027-01-30
Joenja
children with APDS
sNDA
94%
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
📣 What PHAR Says Is Next
in November 2026 · Leniolisib: “Pharming expects to report Phase II results for leniolisib in CVID patients with immune dysregulation, with or without an identified genetic cause, in November 2026.”
Company press release, Oct 27, 2026 · SEC filing
first half of 2027 · “We now expect enrollment to be completed in the first half of 2027.”
Company press release, Oct 27, 2026 · SEC filing
by the end of 2026 · “For Napazimone (KL1333) for mtDNA-driven mitochondrial disease, we expect approximately 145 of the planned 180 subjects to be enrolled in the pivotal FALCON clinical trial by the end of 2026.”
Company press release, Oct 22, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Regulatory The UK MHRA approved Joenja (leniolisib) as the first treatment specifically for children with APDS in the U.K., according to a press release furnished as Exhibit 99.1. Form 6-K · SEC filing
Oct 27, 2026 ·
Earnings Pharming reported third quarter 2026 financial results with strong revenue growth, Joenja APDS expansion, and CVID topline data expected in November. Form 6-K · SEC filing
Oct 22, 2026 ·
Earnings Pharming Group reported third quarter 2026 revenues above market expectations, according to a press release furnished as Exhibit 99.1 dated October 22, 2026. The filing text does not include the revenue figures. Form 6-K · SEC filing
Oct 14, 2026 ·
Clinical trial Pharming reported positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation, presented at ESID 2026. The filing references a press release for details and figures. Form 6-K · SEC filing
Sep 29, 2026 ·
Leadership Pharming announced a CEO transition in a press release furnished as Exhibit 99.1. The filing text provided does not include the name of the incoming or departing executive. Form 6-K · SEC filing
Sep 22, 2026 ·
Clinical trial Pharming reported positive Phase II topline data for leniolisib in primary immunodeficiencies with immune dysregulation. The data was accepted as a late-breaking abstract at ESID 2026. Form 6-K · SEC filing
Sep 11, 2026 ·
Regulatory FDA approved Joenja as the first treatment for children with APDS in the U.S., per a press release furnished as Exhibit 99.1. The filing text itself contains only the cover page and exhibit index. Form 6-K · SEC filing
Aug 13, 2026 ·
Pharming announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2026 · Phase 3 · Active Trial · Pediatric Patients Aged 4 to 11 Years With APDS Registry primary completion date, not a results date
Oct 2027 · Phase 2 · Recruiting · Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease Registry primary completion date, not a results date
Jul 2028 · Phase 3 · Active Trial · Pediatric Patients Aged 1 to 6 Years With APDS Registry primary completion date, not a results date
Mar 2029 · Phase 2 · Recruiting · Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease Registry primary completion date, not a results date
Aug 2029 · Phase 2 · Active Trial · Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PHAR holds $189.6M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PHAR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.